Jefferies Financial Group Boosts Insulet (NASDAQ:PODD) Price Target to $260.00

Insulet (NASDAQ:PODDFree Report) had its price target upped by Jefferies Financial Group from $255.00 to $260.00 in a research report released on Friday morning, Benzinga reports. Jefferies Financial Group currently has a buy rating on the medical instruments supplier’s stock.

Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. upped their target price on Insulet from $190.00 to $225.00 and gave the company an overweight rating in a report on Friday, February 23rd. Piper Sandler cut their price objective on shares of Insulet from $250.00 to $230.00 and set an overweight rating on the stock in a research report on Friday, February 23rd. Barclays reduced their price target on Insulet from $214.00 to $213.00 and set an equal weight rating for the company in a research report on Monday, February 26th. Wolfe Research raised Insulet from a peer perform rating to an outperform rating and set a $200.00 price target on the stock in a report on Tuesday, May 7th. Finally, Stifel Nicolaus raised their price target on Insulet from $163.00 to $208.00 and gave the company a hold rating in a report on Monday, February 5th. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $239.44.

View Our Latest Stock Report on Insulet

Insulet Stock Down 3.0 %

Insulet stock traded down $4.91 during midday trading on Friday, hitting $160.99. 1,431,672 shares of the stock were exchanged, compared to its average volume of 890,111. Insulet has a 1 year low of $125.82 and a 1 year high of $331.65. The company has a debt-to-equity ratio of 1.72, a current ratio of 3.74 and a quick ratio of 2.75. The firm has a market cap of $11.27 billion, a P/E ratio of 49.13, a P/E/G ratio of 2.91 and a beta of 1.00. The company has a 50 day moving average price of $170.52 and a two-hundred day moving average price of $182.35.

Insulet (NASDAQ:PODDGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.34. The business had revenue of $441.70 million during the quarter, compared to the consensus estimate of $424.05 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The business’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.23 earnings per share. On average, sell-side analysts predict that Insulet will post 3.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.47% of the company’s stock.

Hedge Funds Weigh In On Insulet

A number of large investors have recently modified their holdings of PODD. Consolidated Portfolio Review Corp boosted its position in Insulet by 1.6% during the fourth quarter. Consolidated Portfolio Review Corp now owns 3,713 shares of the medical instruments supplier’s stock valued at $806,000 after purchasing an additional 57 shares during the last quarter. FourThought Financial Partners LLC increased its holdings in Insulet by 1.4% during the fourth quarter. FourThought Financial Partners LLC now owns 4,461 shares of the medical instruments supplier’s stock worth $968,000 after buying an additional 61 shares during the last quarter. Linden Thomas Advisory Services LLC raised its position in Insulet by 1.3% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 5,817 shares of the medical instruments supplier’s stock worth $1,262,000 after acquiring an additional 73 shares in the last quarter. Lindbrook Capital LLC grew its position in shares of Insulet by 64.1% in the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after acquiring an additional 75 shares during the period. Finally, New York Life Investment Management LLC increased its stake in shares of Insulet by 0.8% during the 3rd quarter. New York Life Investment Management LLC now owns 10,035 shares of the medical instruments supplier’s stock worth $1,600,000 after purchasing an additional 82 shares during the last quarter.

Insulet Company Profile

(Get Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Further Reading

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.